Previous Close | 6.20 |
Open | 6.20 |
Bid | 11.00 |
Ask | 12.70 |
Strike | 19.00 |
Expire Date | 2024-08-16 |
Day's Range | 6.20 - 6.20 |
Contract Range | N/A |
Volume | |
Open Interest | 58 |
Shattuck (STTK) will now focus on higher-risk myelodysplastic syndromes and TP53 mutant acute myeloid leukemia indications for lead candidate SL-172154, following encouraging interim data from the phase IB dose expansion study.
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.